Short term simvastatin use in patients with heart failure of ischemic origin. Changes of blood lipids, markers of inflammation and left ventricular function

Kardiologiya

Volumn 46, Issue 5, 2006, Pages 44-49

  Smetanina, I N ^a   Vaulin, N A ^a   Masenko, V P ^a   Gratsiansky, N A ^a  

^a FEDERAL RESEARCH AND CLINICAL CENTER OF PHYSICAL CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY   (Russian Federation)

Author keywords

Heart failure, treatment; Simvastatin; Statin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG ADMINISTRATION; DRUG EFFECT; ECHOGRAPHY; FEMALE; FOLLOW UP; HEART CONTRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; HUMAN; INFLAMMATION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

AGED; C-REACTIVE PROTEIN; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 33747166442     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Kjekhus J., Dunselman P., Blideskog M. et al. on behalf of CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail 2005;7:1059-1069.
2. Tavazzi L., Tognoni G., Franzosi M. G. et al. on behalf of GISSI-HF investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsuturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635-641.
3. Horwich B., Hamilton M.A., Maclellan W.R., Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-224.
4. Rauchaus M., Clark A.L., Doehner W. et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-1944.
5. Latini R., Maggioni A.P., Anand I.S. et al. Statins in symptomatic chronic systolic heart failure. A post-hoc analysis of 5010 patients enrolled in Val-HeFT. Congress. Eur Soc Cardiol 2004;Abstract 1473.
6. Krum H., Bailey M., Meyer W. et al. Impact of statin therapy on clinical outcomes in CHF patients according to beta-blocker use: results of CIBIS II. Congress. Eur Soc Cardiol 2004;Abstract 1474.
7. McMurray J.J.V., Pieper K.S., White H. et al. Possible Beneficial Interaction between Statins and Combination Angiotensin Receptor Blocker (ARB) and ACE Inhibitor Treatment in Patients with Myocardial Infarction: A Post hoc Analysis of the VALsartan In Acute Myocardial iNfarcTion Trial (VALIANT). AHA Scientific Sessions 2005, presentation 2330. http://www.abstractsonline.com/ arch/.
8. Ip J.H., Dickinson M.G., Olshansky B. et al. for the SCD-HeFT Investigators. Does Statin Therapy Decrease Mortality in Patients with Cardiomyopathy? Unanticipated Observations from SCD-HeFT. AHA Scientific Sessions 2005, Presentation Number: 1881. http://www.abstractsonline.com/arch/.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial. Lancet 2003;361:2005-2016.
10. Silver M.A., Langsjoen P.H., Szabo S. et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q(10) to reverse that dysfunction. Am J Cardiol 2004;94:1306-1310.